China Traditional Chinese Medicine Holdings Co 570.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
1.19
-0.83%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Traditional Chinese Medicine Holdings Co
Its shares trade on HKEX under the ticker 570.HK. It has been listed since 7 April 1993. In the fiscal year to 31 December 2024, it reported revenue of CN¥16.51bn and net income of CN¥54.1m. At that date it held total assets of CN¥35.06bn and shareholders' equity of CN¥21.20bn.
China Traditional Chinese Medicine Holdings Co., Ltd. operates as an investment holding company, which engages in the research and development, production and sale of Chinese medicine and pharmaceutical products. The company employs 17,373 full-time employees The firm operates through 12 subsidiaries, including Sinopharm Group Dezhong (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Guangdong Medi-World Pharmaceutical Co., Ltd., Sinopharm Group Luya (Shandong) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Medicinal Material & Slices Co., Ltd., Foshan Winteam Pharmaceutical Sales Company Limited, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Sinopharm Group Jingfang (Anhui) Pharmaceutical Co., Ltd., Sinopharm Group Longlife (Guizhou) Pharmaceutical Co., Ltd., Qinghai Pulante Pharmaceutical Co., Ltd., Guizhou Zhongtai Biological Technology Company Limited and its subsidiaries and Jiangyin Tianjiang Pharmaceutical Co., Ltd. and its subsidiaries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Apr 1993
- Employees
- 17,373
- Website
- china-tcm.com.cn ↗
Leadership
Pay as last reported
- Mr. Jun YangExecutive Chairman of the Board, since 2024
- Mr. Hongjian LiPresident (General Manager), Executive Director, since 2024
- Mr. Lixin ShenVice President, Financial Director
- Mr. Dongji ZhaoChief Compliance Officer, Vice President, Joint Company Secretary, Chief Legal Advisor, since 2013CN¥1.5m
- Mr. Zhangxin HuangVice President
- Mr. Qingshan LanVice President
- Ms. Sau Mei NgJoint Company Secretary
- Mr. Xueren ChengNon-Executive Director, since 2018CN¥2.5m
- Ms. Ru LiNon-Executive Director
- Mr. Qingxin MengNon-Executive Director
- Mr. Kan WangNon-Executive Director
- Mr. Binghua YangNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 66
- Environment
- 96
- Social
- 81
- Governance
- 21
- Direct emissions (scope 1)
- 104,425.2 t
- Energy emissions (scope 2)
- 133,194 t
- Women in the workforce
- 49.37623%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company has a large workforce of 17,373 employees.
- It operates through 12 subsidiaries in the pharmaceutical sector.
- It engages in research, development, production, and sale of Chinese medicine and pharmaceutical products.
Weaknesses
- The company's city location is unknown.
- It has a single sector focus on Health Care Pharmaceuticals.
- The company's website is not specified with a clear purpose.
Opportunities
- The company could expand its operations through its subsidiaries.
- The company has a long history since its IPO in 1993.
- The company could leverage its subsidiaries for market growth.
Threats
- The company's data source is described as untrusted.
- The company's city location is unknown and may affect operations.
- The company's website is not specified with a clear purpose.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.